TY - JOUR
T1 - Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
AU - Dhakal, P.
AU - Bhatt, V. R.
N1 - Funding Information:
VR Bhatt is supported by the 2016-2017 Physician-Scientist Training Program Grant from the College of Medicine, University of Nebraska Medical Center. We extend our gratitude to Dr James N George, MD, University of Oklahoma Health Sciences Center, for kindly reviewing this article and providing useful insight.
Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Diagnosis and management of hematopoietic cell transplant-associated thrombotic microangiopathy (TA-TMA) are very complex and controversial, given multiple ongoing issues and comorbidities in sick transplant recipients. Complement activation via classic and alternative pathways is emerging as a potential pathogenetic mechanism in the development of TA-TMA. Complement-centric diagnostic strategy using functional and genetic tests may possibly support diagnosis, enhance molecular understanding and direct drug development. Complement blockade using eculizumab has shown some promising rates of hematologic responses, however, survival may still be poor. Early discontinuation of calcineurin inhibitor where feasible, use of eculizumab, aggressive infection prophylaxis, close monitoring and early treatment of potential complications including GvHD and organ failure may improve outcomes. A number of complement inhibitors are in the development and may change treatment paradigm. Future studies are important to better understand TA-TMA as a disease process and may aim to confirm the role of complement activation in TA-TMA, enhance diagnostic strategy, determine therapeutic approaches and strategies to reduce the risk of other complications particularly infection and GvHD.
AB - Diagnosis and management of hematopoietic cell transplant-associated thrombotic microangiopathy (TA-TMA) are very complex and controversial, given multiple ongoing issues and comorbidities in sick transplant recipients. Complement activation via classic and alternative pathways is emerging as a potential pathogenetic mechanism in the development of TA-TMA. Complement-centric diagnostic strategy using functional and genetic tests may possibly support diagnosis, enhance molecular understanding and direct drug development. Complement blockade using eculizumab has shown some promising rates of hematologic responses, however, survival may still be poor. Early discontinuation of calcineurin inhibitor where feasible, use of eculizumab, aggressive infection prophylaxis, close monitoring and early treatment of potential complications including GvHD and organ failure may improve outcomes. A number of complement inhibitors are in the development and may change treatment paradigm. Future studies are important to better understand TA-TMA as a disease process and may aim to confirm the role of complement activation in TA-TMA, enhance diagnostic strategy, determine therapeutic approaches and strategies to reduce the risk of other complications particularly infection and GvHD.
UR - http://www.scopus.com/inward/record.url?scp=84992432107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992432107&partnerID=8YFLogxK
U2 - 10.1038/bmt.2016.253
DO - 10.1038/bmt.2016.253
M3 - Review article
C2 - 27775697
AN - SCOPUS:84992432107
SN - 0268-3369
VL - 52
SP - 352
EP - 356
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 3
ER -